Hinweise zu Qualitätskriterien von Zeitschriften
Open-Access-Richtlinie der Helmholtz-Gemeinschaft 2016
CC Licencences
Metriken für Publikationen
Startseite
Login
English
Erweiterte Suche
Durchblättern nach ...
Publikationen im Überblick
HGF Fortschrittsbericht
OA Publikationen
Neue Publikation eintragen
Neue Publikation holen aus...
Fehlende Publikation melden
Ansprechpartner
Hilfe
Bibliometrische Indikatoren
Text
Endnote (RIS)
BibTeX
Verlagsversion
Forschungsdaten
DOI
PMC
 |
Open Access Hybrid |
|
möglich sobald bei der ZB eingereicht worden ist.
Discovery of biomarkers for glycaemic deterioration before and after the onset of type 2 diabetes: Descriptive characteristics of the epidemiological studies within the IMI DIRECT Consortium.
Diabetologia 62, 1601-1615 (2019)
Verlagsversion
Forschungsdaten
DOI
PMC
Aims/hypothesis Here, we describe the characteristics of the Innovative Medicines Initiative (IMI) Diabetes Research on Patient Stratification (DIRECT) epidemiological cohorts at baseline and follow-up examinations (18, 36 and 48 months of follow-up). Methods From a sampling frame of 24,682 adults of European ancestry enrolled in population-based cohorts across Europe, participants at varying risk of glycaemic deterioration were identified using a risk prediction algorithm (based on age, BMI, waist circumference, use of antihypertensive medication, smoking status and parental history of type 2 diabetes) and enrolled into a prospective cohort study (n = 2127) (cohort 1, prediabetes risk). We also recruited people from clinical registries with type 2 diabetes diagnosed 6-24 months previously (n = 789) into a second cohort study (cohort 2, diabetes). Follow-up examinations took place at similar to 18 months (both cohorts) and at similar to 48 months (cohort 1) or similar to 36 months (cohort 2) after baseline examinations. The cohorts were studied in parallel using matched protocols across seven clinical centres in northern Europe. Results Using ADA 2011 glycaemic categories, 33% (n = 693) of cohort 1 (prediabetes risk) had normal glucose regulation and 67% (n = 1419) had impaired glucose regulation. Seventy-six per cent of participants in cohort 1 was male. Cohort 1 participants had the following characteristics (mean +/- SD) at baseline: age 62 (6.2) years; BMI 27.9 (4.0) kg/m(2); fasting glucose 5.7 (0.6) mmol/l; 2 h glucose 5.9 (1.6) mmol/l. At the final follow-up examination the participants' clinical characteristics were as follows: fasting glucose 6.0 (0.6) mmol/l; 2 h OGTT glucose 6.5 (2.0) mmol/l. In cohort 2 (diabetes), 66% (n = 517) were treated by lifestyle modification and 34% (n = 272) were treated with metformin plus lifestyle modification at enrolment. Fifty-eight per cent of participants in cohort 2 was male. Cohort 2 participants had the following characteristics at baseline: age 62 (8.1) years; BMI 30.5 (5.0) kg/m(2); fasting glucose 7.2 (1.4) mmol/l; 2 h glucose 8.6 (2.8) mmol/l. At the final follow-up examination, the participants' clinical characteristics were as follows: fasting glucose 7.9 (2.0) mmol/l; 2 h mixed-meal tolerance test glucose 9.9 (3.4) mmol/l. Conclusions/interpretation The IMI DIRECT cohorts are intensely characterised, with a wide-variety of metabolically relevant measures assessed prospectively. We anticipate that the cohorts, made available through managed access, will provide a powerful resource for biomarker discovery, multivariate aetiological analyses and reclassification of patients for the prevention and treatment of type 2 diabetes.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Times Cited
Scopus
Cited By
Cited By
Altmetric
7.113
1.752
7
12
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern
Publikationstyp
Artikel: Journalartikel
Dokumenttyp
Wissenschaftlicher Artikel
Schlagwörter
Diet ; Ectopic Fat ; Genome ; Glycaemic Control ; Insulin Secretion ; Insulin Sensitivity ; Personalised Medicine ; Physical Activity ; Prediabetes ; Type 2 Diabetes; Beta-cell Function; Glucose-tolerance; Insulin Sensitivity; Cohort Profile; Fat-content; Design; Tests; Resistance; Release; Risk
Sprache
Veröffentlichungsjahr
2019
HGF-Berichtsjahr
2019
ISSN (print) / ISBN
0012-186X
e-ISSN
1432-0428
Zeitschrift
Diabetologia
Quellenangaben
Band: 62,
Heft: 9,
Seiten: 1601-1615
Verlag
Springer
Verlagsort
Berlin ; Heidelberg [u.a.]
Begutachtungsstatus
Peer reviewed
Institut(e)
Molekulare Endokrinologie und Metabolismus (MEM)
POF Topic(s)
30201 - Metabolic Health
Forschungsfeld(er)
Genetics and Epidemiology
PSP-Element(e)
G-505600-003
WOS ID
WOS:000478770300009
PubMed ID
31203377
Erfassungsdatum
2019-06-25